, Columnist
The Bill For Valeant's Decent Year Just Came Due
The drugmaker's problems weren't averted, just pushed into the future.
Valeant Pharmaceuticals International Inc. signage is displayed outside the company's headquarters in Bridgewater Township, New Jersey, on Aug. 4, 2016.
This article is for subscribers only.
Valeant Pharmaceuticals International Inc., long the sick man of the pharma world, actually had a decent 2017.
It chipped away at its massive debt pile, pushed some debt obligations into the future, and stabilized parts of its business. But Valeant's 2017 results and 2018 guidance, released Wednesday morning, illustrate we still don't know when its long-promised turnaround will arrive -- or where its bottom will be.